PASG

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Countouriotis AthenaInsider --10.5k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable10.5k shares -- --
Gowen MaxineInsider --10.5k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable10.5k shares -- --
Kapadia SandipInsider --10.5k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable10.5k shares -- --
Kassberg Thomas RichardInsider --10.5k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable10.5k shares -- --
Porter DerrellInsider --10.5k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable10.5k shares -- --
Sondhi DolanInsider --10.5k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable10.5k shares -- --

News

globenewswire.comPassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updatesglobenewswire.comApr 20

Trade PASG

About Passage Bio, Inc.

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

CEO: William Chou
IPO Date: Feb 28, 2020

Market Data

Open: $5.46
High: $5.89
Low: $4.92
Volume: 71.9K
52W High: $20.00
52W Low: $3.94

Valuation

Market Cap: $16M
Enterprise Value: $-11M

Financials

Free Cash Flow: $-32M
Revenue: $0
Net Income: $-46M
Cash: $46M
Debt: $24M

Events

EarningsAug 11

EPS est. -2.438